Study guide
2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies
Key Takeaways Explain This Topic AI
Powder flowability and compressibility dictate tablet weight uniformity, evaluated via Angle of Repose, Carr's Index, and Hausner Ratio.
Tablet excipients serve distinct functional roles; reducing sugars like lactose can trigger Maillard browning when combined with primary amine APIs.
Superdisintegrants accelerate tablet breakup via rapid water wicking and swelling, whereas hydrophobic lubricants like magnesium stearate can impede dissolution if over-blended.
Enteric coatings utilize pH-dependent polycarboxylic acid polymers that remain insoluble at gastric pH but dissolve rapidly upon entering the small intestine.
Osmotic pump delivery systems (OROS) deliver drug at a constant zero-order rate independent of GI pH and motility, releasing an insoluble ghost shell eliminated in the stool.
Last updated: August 2026
Powder Micromeritics and Granulation Technologies
Solid dosage forms represent over 70 % 70\% 70% of all pharmaceutical prescriptions dispensed in Canada. The manufacture of uniform, robust tablets and capsules depends directly on the science of small particles ( micromeritics ) and powder flow dynamics.
Characterization of Powder Flow and Compressibility
Angle of Repose ( θ \theta θ ): The maximum angle possible between the surface of a powder pile and the horizontal plane ( tan θ = h r \tan\theta = \frac{h}{r} tan θ = r h ).
- θ < 25 ∘ \theta < 25^\circ θ < 2 5 ∘ : Excellent flow
- θ = 25 ∘ to 30 ∘ \theta = 25^\circ\text{ to }30^\circ θ = 2 5 ∘ to 3 0 ∘ : Good flow
- θ = 30 ∘ to 40 ∘ \theta = 30^\circ\text{ to }40^\circ θ = 3 0 ∘ to 4 0 ∘ : Fair flow (passable)
- θ > 40 ∘ \theta > 40^\circ θ > 4 0 ∘ : Poor flow / cohesive powder
Carr's Compressibility Index ( C C C ): C = ( ρ tapped − ρ bulk ρ tapped ) × 100 % C = \left(\frac{\rho_{\text{tapped}} - \rho_{\text{bulk}}}{\rho_{\text{tapped}}}\right) \times 100\% C = ( ρ tapped ρ tapped − ρ bulk ) × 100%
- C < 10 % C < 10\% C < 10% : Excellent flowability
- C = 11 % to 15 % C = 11\%\text{ to }15\% C = 11% to 15% : Good flowability
- C > 25 % C > 25\% C > 25% : Poor flowability (requires granulation or glidants)
Hausner Ratio ( H H H ): H = ρ tapped ρ bulk H = \frac{\rho_{\text{tapped}}}{\rho_{\text{bulk}}} H = ρ bulk ρ tapped
H < 1.25 H < 1.25 H < 1.25 : Indicates free-flowing powder
H > 1.35 H > 1.35 H > 1.35 : Indicates highly cohesive powder prone to arching and rat-holing in tablet press hoppers.
Granulation Methods
Direct Compression: Powder blend containing API and directly compressible excipients is compressed without prior granulation. It is the simplest and most cost-effective method, ideal for heat- and moisture-sensitive drugs, but requires excellent powder flow and compressibility (e.g., using spray-dried lactose or microcrystalline cellulose).
Dry Granulation (Roller Compaction / Slugging): Powders are compacted under high mechanical pressure into ribbons or large slugs, then milled into uniform granules. This method avoids all water and heat, making it suitable for moisture-sensitive APIs (e.g., aspirin, effervescent salts).
Wet Granulation: Powder blend is mixed with a liquid binder solution to form a wet mass, passed through screens, dried, and sized. It ensures superior content uniformity for low-dose drugs and improves flowability, but involves moisture and thermal exposure.
Tablet Excipients and Formulation Science
Tablet formulations consist of active ingredients intimately blended with functional excipients, each serving a vital role in processing, stability, or drug release.
Excipient Class Functional Role Common Examples Critical Formulation Notes
Diluent (Filler) Provides tablet bulk when API dose is small Lactose (anhydrous/monohydrate), Microcrystalline Cellulose (MCC, Avicel), Mannitol, Dicalcium phosphate Lactose undergoes Maillard browning with primary amines (e.g., fluoxetine, sertraline). Mannitol provides a cooling sensation for chewable tablets.
Binder (Granulator) Imparts cohesive strength to powder granules Povidone (PVP), Hydroxypropyl methylcellulose (HPMC), Pregelatinized starch Excessive binder prolongs tablet disintegration time and slows dissolution.
Disintegrant Promotes rapid tablet breakup in aqueous GI fluids Starch, Croscarmellose sodium, Sodium starch glycolate, Crospovidone Cross-linked superdisintegrants swell rapidly ( > 200 % > 200\% > 200% ) and draw water by capillary wicking at low concentrations ( 2 − 5 % 2-5\% 2 − 5% w/w).
Lubricant Reduces friction between tablet surface and die wall during ejection Magnesium stearate, Stearic acid, Sodium stearyl fumarate Magnesium stearate is hydrophobic; over-blending coats API particles, retarding tablet wetting and dissolution.
Glidant Improves powder flow by reducing interparticle friction Colloidal silicon dioxide (Aerosil/Cab-O-Sil), Talc Used at low concentrations ( 0.1 − 0.5 % 0.1-0.5\% 0.1 − 0.5% w/w); excessive amounts worsen flow.
Tablet Manufacturing Defects and Quality Standards
During high-speed rotary tableting, improper formulation or machine settings cause characteristic manufacturing defects:
Capping: Partial or complete separation of the top or bottom crown of a tablet from the main body, caused by air entrapment, excessive fine particles, or high compression speeds.
Lamination: Separation of a tablet into two or more distinct horizontal layers, caused by air entrapment during pre-compression or relaxation of elastic materials.
Sticking and Picking: Granulation adhering to the die wall (sticking) or punch faces, resulting in missing fragments from the tablet face or embossed lettering (picking); caused by excessive moisture or inadequate lubrication.
Mottling: Unequal, non-uniform distribution of color across the tablet surface, caused by migration of soluble dyes during wet granule drying.
Friability Testing (USP Standard): Tablets are rotated in a drum (Roche friabilator) for 100 revolutions (25 rpm for 4 minutes). The maximum acceptable weight loss for uncoated commercial tablets is < 1.0 % < 1.0\% < 1.0% , ensuring resistance to chipping during automated packaging and transport.
Capsule Dosage Forms: Hard Gelatin vs. Softgels
Capsules enclose dry powders, granules, pellets, or non-aqueous liquids within a soluble gelatin or polymeric shell. Capsules:
- |-- Hard Gelatin / HPMC Capsules
- | |-- Two-piece (Body + Cap)
- | |-- Moisture content: Gelatin (13-16%), HPMC (4-6% for moisture-sensitive APIs)
- | |-- Standard Sizes: 000 (largest, ~1.37 mL) to 5 (smallest, ~0.13 mL)
- |-- Soft Gelatin Capsules (Softgels)
- |-- One-piece, hermetically sealed
- |-- High plasticizer content (Glycerin, Sorbitol) yielding flexible shell
- |-- Fill: Non-aqueous lipophilic liquids, PEG solutions, self-emulsifying oils
- |-- Incompatibilities: > 5% water fills, low MW aldehydes (gelatin cross-linking)
- Modified-Release Technologies and Formulations
Modified-release dosage forms alter the timing, rate, or anatomical site of drug release to optimize therapeutic efficacy, reduce dosing frequency, and minimize adverse events.
Enteric Coating (Delayed-Release)
Enteric coatings protect acid-labile drugs from gastric degradation (e.g., proton pump inhibitors like omeprazole) or protect the gastric mucosa from irritating drugs (e.g., enteric-coated aspirin).
Mechanism: Enteric polymers contain free carboxylic acid side chains that remain un-ionized and water-insoluble at acidic gastric pH ( 1.0 to 3.0 1.0\text{ to }3.0 1.0 to 3.0 ). When the dosage form empties into the duodenum and jejunum ( pH > 5.5 to 6.8 \text{pH} > 5.5\text{ to }6.8 pH > 5.5 to 6.8 ), the carboxyl groups ionize into soluble carboxylate salts, triggering rapid polymer dissolution.
Key Polymers: Cellulose acetate phthalate (CAP), Hydroxypropyl methylcellulose phthalate (HPMCP), Methacrylic acid-ethyl acrylate copolymers ( Eudragit L dissolves at pH ≥ 5.5 \text{pH} \ge 5.5 pH ≥ 5.5 ; Eudragit S dissolves at pH ≥ 7.0 \text{pH} \ge 7.0 pH ≥ 7.0 ).
Extended-Release (ER) Mechanisms
Hydrophilic Swellable Matrix: The API is uniformly blended with a high-molecular-weight hydrophilic polymer such as hydroxypropyl methylcellulose (HPMC / Hypromellose) . Upon contact with gastrointestinal fluid, the surface polymer hydrates to form a viscous, rubbery gel layer. Drug molecules release via a combination of diffusion through the gel layer and gradual polymer erosion.
Insoluble / Lipid Matrix: The API is embedded in a rigid, non-swellable matrix of ethylcellulose, carnauba wax, or polyvinyl acetate. Gastrointestinal fluids penetrate the tortuous pores of the matrix to dissolve the drug, which leaches out by passive diffusion. The insoluble porous matrix shell remains intact and is excreted in the feces.
Osmotic-Controlled Release Oral Delivery Systems (OROS):
Architecture: A rigid tablet core containing the API and an osmotic driving agent (e.g., sodium chloride) is encapsulated by a water-permeable, drug-impermeable semipermeable cellulose acetate membrane. A precision laser-drilled orifice penetrates the membrane.
Mechanism: Water from the GI tract enters the core osmotically across the semipermeable membrane, generating hydrostatic pressure that pumps the drug solution or suspension out through the laser-drilled orifice at a constant zero-order rate ( d M / d t = constant dM/dt = \text{constant} d M / d t = constant ).
Clinical Advantage: Drug delivery rate is independent of gastrointestinal pH, motility, enzymatic activity, and fed or fasted state (e.g., nifedipine extended-release / Adalat XL , methylphenidate / Concerta ).
Patient Counseling: Patients must be reassured that the non-absorbable polymer shell ( "ghost tablet" ) will appear intact in their stool after complete drug delivery.
Critical Safety Considerations: Dose Dumping and Manipulation
Dose Dumping: A sudden, premature release of the entire drug payload from a modified-release formulation, resulting in toxic peak plasma concentrations. This can occur when modified-release opioids or antihypertensives are crushed, chewed, or co-ingested with ethanol, which dissolves the rate-controlling polymer barrier.
Do Not Crush Guidelines: Pharmacists must consult authoritative references (e.g., ISMP and Health Canada "Do Not Crush" lists) to prevent inadvertent crushing of extended-release or enteric-coated medications for administration via enteral feeding tubes.